Angermayer vs. Doblin: R-MDMA Race to Market and Clinical Trials

“these data suggest that R-MDMA could be a more viable therapeutic option for the treatment of PTSD and other disorders for which S/R-MDMA is currently being investigated” since “R-MDMA unlike racemic MDMA, did not increase locomotor activity, produce signs of neurotoxicity, or increase body temperature.

A key pharmacological difference between R-MDMA and racemic MDMA is that R-MDMA has much lower potency as a dopamine releaser. Together, these results indicate that the prosocial and therapeutic effects of S/R-MDMA may be SEPARABLE from the stimulant, thermogenic, and potential neurotoxic effects.”

August 13, 2024

Psilomethoxin Affidavit of Professor Elizabeth Gardner the Program Director of Graduate Studies in Forensic Science in the Criminal Justice Department at the University of Alabama at Birmingham and Regional Editor for North America, Forensic Science Review

The authors make the claim that the enzymatic reactions that produce psilocin are “unexpected” for 5-MeO-DMT and therefore the synthesis of psilomethoxin is “unsubstantiated.” The authors are ignoring the 1988 study by Jochen Gartz where the transformation of diethyl‐tryptamine into 4‐hydroxy‐N,N‐diethyltryptamine (3.3%) and a minor quantity of 4‐phosphoryloxy‐N,N‐diethyltryptamine (≤0.8%) was produced by the Psilocybe cubensis mushroom in an example of biosynthesis of tryptamines. This IS a peer-reviewed article: Gartz J. Biotransformation of tryptamine derivatives in mycelial cultures of Psilocybe. Journal of basic microbiology. 1989;29(6):347-52.